Decode Genetics Receives Nasdaq Delisting Notice | GenomeWeb

NEW YORK (GenomeWeb News) – Decode Genetics said today that it has received a delisting notice from Nasdaq following the firm's announcement last week that it has filed for Chapter 11 bankruptcy protection.

Nasdaq informed Decode that it will suspend trading in the company’s common stock as of Nov. 30, 2009, and that it will file a Form 25-NSE with the US Securities and Exchange Commission to remove Decode's common stock from listing on Nasdaq, unless the company files an appeal to the Nasdaq Listing Qualifications Panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.